 Oil composition |
| What is claimed is: 1. An oil composition, comprising about 0.1 to 59.8% by weight of a ... |
|
| Blocking agents of EDRF effect or formation for the treatment of shock |
| We claim: 1. A therapeutical composition of matter for the treatment by perfusion of shock states ... |
|
| Use of polyamines as ionic-channel regulating agents |
| OF THE PREFERRED EMBODIMENTS The disclosure of any and all cited documents including literature ... |
|
| Inhibitor of ceramidase |
| It is a general object of the invention to provide a method of selecting compounds that cause ... |
|
| Treatment of bone disorders with adrenomedullin |
| OF THE INVENTION It is believed that one skilled in the art can, based on the description herein, ... |
|
| 99MTC(III) myocardial imaging agents and method of use |
| OF THE INVENTION The technetium compounds of the present invention which have been found most ... |
|
| 1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents |
| OF THE INVENTION Compounds of the formula I may be prepared as illustrated in the following ... |
|
| Vaginal sponge delivery system |
| These and other objects of the invention are achieved in a product which broadly comprises (a) a ... |
|
| Controlled release formulation |
| What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation ... |
|
| Formulations providing three distinct releases |
| We claim: 1. A therapeutic composition for oral administration consisting essentially of a ... |
|
|
Pharmaceutical composition containing diltiazem and angiotensin-converting enzyme inhibitor
| Details |
Inventors: Cavero, Icilio; Elkik, Francois; Hicks, Peter; Muller, Jean-Claude;
Assignee: Synthelabo (Paris, FR)
Primary Examiner: Robinson; Allen J.
Assistant Examiner:
Attorney, Agent or Firm: Wegner, Cantor, Mueller & Player
Compositions of diltiazem and angiotensin-converting enzyme inhibitor useful for the treatment of hypertension, cardiac insufficiency and coronary insufficiency. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A pharmaceutical composition containing a combination of 10-360 mg of diltiazem and 1-100 mg of an angiotensin-converting enzyme inhibitor, enalapril useful for the treatment of hypertension, cardiac insufficiency, and coronary insufficiency, such that the anti-hypertensive effect observed upon combined administration of diltiazem and said angiotensin-converting enzyme inhibitor is greater than the sum of the individual anti-hypertensive effects observed upon the separate administration of diltiazem and said angiotensin-converting enzyme inhibitor alone.
2.
A method for treatment of hypertension, cardiac insufficiency or coronary insufficiency comprising administering to a subject suffering therefrom a pharmaceutical composition containing a combination of 10 to 360 mg of diltiazem and 1 to 100 mg of an angiotensin-converting enzyme inhibitor, enalapril, such that the anti-hypertenive effect observed upon administration of the combined administration of diltiazem and said angiotensin-converting enzyme inhibitor is greater than the sum of the individual anti-hypertensive effects observed upon the separate administration of diltiazem and said angiotensin-converting enzyme inhibitor alone.
Description:
BACKGROUND OF THE INVENTION The present invention relates to pharmaceutical compositions containing diltiazem and an angiotensin-converting enzyme inhibitor useful in the treatment of hypertension.
Hypertension is a field in which polytherapy is encountered extremely frequently.
Calcium inhibitors occupy a position of increasing importance in the field of hypertension.
They are being recommended as a first line treatment in elderly hypertensive patients, who are known to be very numerous.
It appears, however, that combinations of calcium inhibitors with diuretics and/or .
beta.
-blockers are not completely satisfactory.
According to indication, diltiazem is beneficial in that it is well tolerated, and is currently gaining as leader in the field of angina pectoris; however, its relatively weak peripheral vasodilatory action could constitute a handicap
|
|
Vasodialators 
